Val'dman EA - Search Results

1

[The possibilities of using himantane in the treatment of Parkinson's disease].

Katunina EA, Petrukhova AV, Avakian GN, Val'dman EA, Nerobkova LN, Voronina TA, Saiadian KhS. Katunina EA, et al. Among authors: val dman ea. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(6):24-7. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID: 18577930 Clinical Trial. Russian.

2

[Clinico-neurophysiologic and experimental study of the peculiarities of adamantan-sulphate treatment in Parkinson's disease].

Avakian GN, Voronina TA, Val'dman EA, Nerobkova LN, Katunina EA, Samoĭlova EV. Avakian GN, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104(9):18-22. Zh Nevrol Psikhiatr Im S S Korsakova. 2004. PMID: 15490936 Russian.

3

[Functional brain activity in patients with Parkinson's disease during amantadin-sulfate therapy].

Arakelian RK, Nerobkova LN, Katunina EA, Val'dman EA, Kapitsa IG, Voronina TA, Avakian GN, Gusev EI. Arakelian RK, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(4):17-21. Zh Nevrol Psikhiatr Im S S Korsakova. 2005. PMID: 15875939 Russian.

4

[Comparative study of himantane and amantadine effects in experimental intracerebral posttraumatic hematoma].

Kotel'nikova SO, Nepoklonov AV, Kokshenev II, Ivanova EA, Kraĭneva VA, Val'dman EA, Garibova TL, Voronina TA. Kotel'nikova SO, et al. Among authors: val dman ea. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(9):63-6. Zh Nevrol Psikhiatr Im S S Korsakova. 2012. PMID: 23235415 Russian.

5

[Oxidative stress and Parkinson's disease: mechanisms and perspectives of treatment].

Katunina EA, Titova NV, Malykhina EA, Gasanov MG, Makarova AA, Voronina TA, Nerobkova LN, Valdman EA, Avakyan GN. Katunina EA, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(7):141-145. doi: 10.17116/jnevro201511571141-145. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PMID: 26356527 Review. Russian. No abstract available.

6

[Estimation of the protective effect of the novel potential antiparkinsonian agent himantane against MPTP neurotoxicity].

Val'dman EA, Nerobkova LN, Voronina TA. Val'dman EA, et al. Eksp Klin Farmakol. 2004 Jan-Feb;67(1):7-10. Eksp Klin Farmakol. 2004. PMID: 15079899 Russian.

7

[Immunotropic activity of a potential antiparkinson agent himantane].

Nezhinskaia GI, Val'dman EA, Nazarov PG, Voronina TA. Nezhinskaia GI, et al. Eksp Klin Farmakol. 2001 Mar-Apr;64(2):60-3. Eksp Klin Farmakol. 2001. PMID: 11548451 Russian.

8

[Comparative study of neurophysiological effects of adamantane derivatives in the experimental parkinsonism model].

Katunina EA, Samoĭlova EV, Val'dman EA, Nerobkova LN, Voronina TA, Avakian GN. Katunina EA, et al. Eksp Klin Farmakol. 2004 Mar-Apr;67(2):16-8. Eksp Klin Farmakol. 2004. PMID: 15188753 Russian.

9

[Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease].

Nepoklonov AV, Kapitsa IG, Ivanova EA, Voronina TA, Val'dman EA. Nepoklonov AV, et al. Among authors: val dman ea. Eksp Klin Farmakol. 2012;75(11):3-6. Eksp Klin Farmakol. 2012. PMID: 23323324 Russian.

10

[Effect of hemantane on bioelectric activity of brain in mice with MPTP-induced Parkinson syndrome].

Kapitsa IG, Kokshenev II, Nerobkova LN, Val'dman EA, Voronina TA. Kapitsa IG, et al. Among authors: val dman ea. Eksp Klin Farmakol. 2013;76(4):3-6. Eksp Klin Farmakol. 2013. PMID: 23762980 Russian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters